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Summary 
Both superantigens (SAG) and many anti-TCR monoclonal antibodies (mAb) have specificity 
for the V[3 region of the TCR encoded by TCRBV genes. For instance the bacterial SAG staph- 
ylococcal enterotoxin E  (SEE),  the retroviral SAG MTV-9 and the mAb OT145  each react 
with human T  cells expressing BV6S7. This BV gene encodes two common alleles.  We found 
that  SEE  and  the  mAb  preferentially  activate  T  cells  expressing  BV6S7"1  as  opposed  to 
BV6S7"2, but Mtv-9 activates T  cells expressing either allele.  Thus binding to the TCR differs 
between the two SAGs. A  mutation in the TCR HVR-4 region of BV6S7"1  (G72E), where 
the two BV6S7 alleles differ, indicated that HVR-4 is a component of the binding site for SEE 
and for the mAb OT145. BV6S7"2 has a charged E72 which may result in electrostatic repul- 
sion of SEE,  as SEE contains a similarly acidic aspartic acid residue at a TCR interaction site 
(204D). 
S 
uperantigens are powerful T  cell mitogens produced by 
bacteria, mycoplasma and certain viruses. In contrast to 
nominal peptide antigens they do not require antigen pro- 
cessing and presentation to T  cells is not restricted to indi- 
vidual MHC  alleles.  However,  efficient presentation  does 
require  binding  of the  superantigens  (SAG) 1 to  an MHC 
class II molecule at the surface of an antigen presenting cell. 
Typically superantigens activate T  ceils  that express T  cell 
antigen receptors (TCR) using specific BV genes. 
The  bacterial  SAG  SEE  (1),  the  retroviral SAG Mtv-9 
(2), and the mAb OT145  (3), have each been shown to re- 
act with human T  ceils expressing BV6S7, previously des- 
ignated VI36.7 (4). There are two naturally occurring alleles 
of this gene,  which  differ by two  nonconservative amino 
acids substitutions  at positions 38  and 72  (4,  5).  BV6S7"1 
(V136.7a) encodes $38  (serine) and G72 (glycine) , whereas 
BV6S7"2 (VI36.7b)  encodes R38 (arginine) and E72 (gluta- 
mic acid).  Position 72 is located in hypervariable region-4 
(HVR4)  of the  TCR  {3  chain.  HVR-4 is a region  of the 
TCR  J3 chain previously implicated in recognition of bac- 
terial and viral SAGs, including SEB, SEC1, SEC2, Mtv-7, 
and Mtv-9 (6-9).  Therefore, we tested T  cell responses to 
TAbbreviations used in this paper: RAM, rabbit anti-mouse; SAG, superanti- 
gens; SEE, Staphylococcal  enterotoxin E. 
SEE  and Mtv-9 SAG to assess whether these SAG distin- 
guish between the two alleles of BV6S7. 
In addition to HVR-4 residues, TCR residues outside of 
HVR-4 have also been shown to influence SAG reactivity 
(10-14).  Moreover, the precise topology of the interaction 
between  SAG  encoded  residues  and  TCR  residues is  still 
unresolved  as  co-crystals  involving  SAG  and  TCR  have 
not yet been described.  There is data on the SAG residues 
involved  in  interactions  with  TCR.  For  instance,  the 
COOH-terminal residues  of the  Mtv SAGs are polymor- 
phic and therefore thought to be responsible for TCR BV 
specificity  (15,  16).  Several  studies  have  pinpointed  two 
residues on SEE that provide for the TCR BV specificity of 
this SAG (P203  and D204)  (17-19).  Using these previous 
results and the data described herein we propose a model of 
interaction between TCR BV6S7 position 72 with specific 
residues  of SEE  and  describe relative positions within  the 
trimolecular complex for TCR, superantigen and MHC. 
Materials and Methods 
Cells and mAbs.  Heparinized  peripheral  blood was  obtained 
from normal  donors  with known homozygous or heterozygous 
BV6S7 genotype (4). Mononuclear cells were isolated by Ficoll 
Hypaque gradient separation and in some cases T cells were fur- 
ther separated by rosetting with neuraminidase-treated  sheep red 
blood cells. Cell  separations with  GAM-coated magnetic  beads 
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ously described  (20). These separations were monitored by stain- 
ing before  and after the separation.  The efficiency of this proce- 
dure  is  ~90%.  DAP  row-9  is  a  statJle transfectant  expressing 
HLA-DR1  and the Mtv-9 sag gene cloned in to the  expression 
vector  pHAb-Aprl-neo on a mouse  DAP fibroblast background. 
The transfectants were cultured in RPMI-1640 10% fetal bovine 
serum,  1% L-glutamine,  1% penicillin-streptomycin  in the pres- 
ence of G418.  The mAb OT145 is specific for BV6S7 as previ- 
ously described  (4,  21).  Other TCR BV-specific  mAbs are de- 
scribed  elsewhere  (22). The Jurkat  transfectants,  YP59.44  and 
m72, have previously been described  (3). Staphylococcal  entero- 
toxin E  (SEE) was obtained from Toxin Technology Inc., and 
used at 0.1 ng/ml. 
Cultures.  For co-cultures of T  cells with Mtv-transfectants, 
the  latter  were  first treated  with mitomycin C,  50  mcg/ml, to 
stop further proliferation.  For other co-cultures irradiated  (3,000 
rads) autologous non-T cells were pulsed with the superantigens 
SEE or SEA (1  ng/ml or as indicated),  then washed  and added 
back to the autologous T cells at a 1:1 ratio. T cells were preincu- 
bated with OT145 ascites (dil.  1:500) for  1 h  and then washed 
and cultured with  APCs  (irradiated  non-T cell  fraction from 
PBMNC). PHA was used at  1 ~g/ml. Cultures were in RPMI 
1640,  10% fetal calf serum,  1% penicillin and 1% streptomycin 
with added  glutamine, hlL-2 (50 U/ml; Boehringer Mannheim, 
Indianapolis,  IN) was added after 3-4 d. 
Immunofluorescence.  One-color and two-color flow cytomet- 
ric analysis was performed as follows. 2 X  10  ~ cells were first in- 
cubated with saturating  concentrations of anti-BV mAbs for  40 
min on ice in RPMI 1640,  1% fetal bovine serum (FBS). Anti- 
CD3, anti-CD4, anti-CD8, and the negative control mAb FFa26 
were used as controls.  After incubation, ceils were washed  with 
RPMI 1640  1% FBS and then stained with goat  anti-mouse Ig 
conjugated to FITC (GAM-FITC; Tago Inc., 1:50 dilution) on 
ice  for  30  rain. After  washing,  5,000  cells were  analyzed  on a 
Coulter  EPICS  cytofluorograph  (Hialeah,  FL). For  two-color 
staining,  mAb FFa26  (lgG1)  was  added  for  20  min on ice  to 
block unoccupied binding sites of GAM-FITC antibodies.  Cells 
were washed  and then incubated with phycoerythrin-conjugated 
anti-CD8 or anti-CD4 mAb (Immunotech) for 30 min on ice. 
IntracellularCa  §  Studies.  The  Jurkat  transfectants,  YP59.44 
and m72, were collected,  washed  and suspended at 107 cells/ml. 
The cells were labeled with Indo-1 (Molecular  Probes,  Eugene, 
OR) at 5 mM for 1 h at 37~  in the dark. The washed cells were 
resuspended  in PBS,  I  mM Ca ++,  1 mM Mg  §  Fluorescence 
was monitored in a spectrofluorometer.  Stimuli were added  un- 
der continuous stirring of 106 cells in a 0.4 ml volume. For the 
addition  of  SEE  in  the  presence  of  antigen-presenting cells 
(APCs) the MHC class II positive  8866-P B lymphoblastoid cell 
line (107 cells) was added at either a 1:1 or a 3:1  cell ratio before 
addition of SEE. 
TCR BV Use by PCR.  RNA was isolated  using RNAzol B 
(CINNA/BIOTECX Labs., Houston, TX)  and cDNA synthe- 
sized with random hexanucleotide primers  and m-MLV reverse 
transcriptase. Primers for BV genes paired with a BC primer were 
used  to  amplify  cDNA  by  PCR  as  described  elsewhere  (23). 
cDNA from PHA-activated normal T  cells indicated that all BV 
primers  were  able  to  amplify  DNA from  the  specified  subsets 
(BV1, 2, 3, 4,  5S1, 5S2/3, 6,  7, 8S1, 8S4,  9,  10,  11,  12,  13S1, 
13S2,  14,  15,  16,  17,  18,  19, 20).  The BV6 sense primer used, 
primer I in (4), is a 19-mer with complete sequence identity with 
all BV6  genes  and nearly all of their allelic variants.  The A/T 
overhang vector PCR2000 was used to subclone PCR products 
as described elsewhere  (24). Single transformed  bacterial colonies 
were selected  for sequencing of the plasmid inserts. Sequencing 
reactions  were performed with sequenase,  version 2.0  DNA se- 
quencing kit (United States Biochemical, Cleveland, OH). 
PCR to Detect BV6S7 Allele Use.  BV6S7"1 contains  a  BamHI 
site which is not present in BV6S7"2 (4). Therefore, BV6S7 allele 
usage was assessed by PCR with primers  that straddle the poly- 
morphic BamHI site and by digestion of the PCR product with 
BamHI as described  by Vissinga et al.  (25). RNA was prepared 
and  cDNA  synthesized.  BV6S7  primers  were  5'GTCACA- 
GAGAAGGGAAAGG3'  (sense) and  5'CGGCCGAGTCCT- 
CCTGCTG3' (anti-sense).  These primers  yield a 237-bp PCR 
product. The sense primer was end-labeled with ~/32p ATP using 
phosphonucleotide  kinase (Boehringer Mannheim). The PCR mix 
contained template  cDNA derived from ~50,000 cells, 100 ng of 
each primer, 2.5 mM MgC1, 0.4  mM dNTPs, 0.8 U  Taq poly- 
merase  (Promega,  Madison, WI)  in 50  mM KC1, 10  mM Tris 
HC1  (pH  9),  l{/,} Triton-X. PCR was performed for  30  cycles: 
94~  ￿  1 rain, 60~  X  1 rain, 72~  5(  I rain, with a hot start 
and a final extension at 72~  ￿  10 rain. The amplified  cDNA 
was then digested using BamHI (New England Biolabs, Beverly, 
MA) under optimal conditions, run on a 10% polyacrylamide  gel 
which was exposed to x-ray film. The intact PCR product mea- 
sures 237  bp  (representing  BV7S7"2)  and the  upstream labeled 
fragment from the BamHI digest measures  189 bp (representing 
BV6S7"1).  The relative intensity of these two bands on exposed 
x-ray film was assessed with a scanner and the program IMAGE  R. 
The nomenclature used herein for TCR BV genes is according 
to the Genbank L36092 entry for the entire TCR BV locus. An 
alternative  nomenclature has  recently been proposed  in which 
BV6S7 was designated BV6S5 (26) and Rowen et al. propose  the 
name 7-2 (27). 
Results 
SEE  Activates  BV6S7"1,  but  Not  BV6S7"I  G72E,  Ex- 
pressingJurkat  T  Cells.  A Jurkat transfectant expressing TCR 
BV6S7"1  (YP55.49)  was compared with a Jurkat transfec- 
rant expressing a mutated TCR BV6S7"1  chain with a sub- 
stitution in the HVR4 region, G72E. This substitution was 
chosen because it represents the naturally occurring BV6S7"2 
allele which encodes E72. Both transfectants expressed the 
identical Jurkat derived rearranged TCR  A  gene (3).  SEE 
pulsed APC were added to Jurkat cells, loaded with Indo-1, 
and intracellular Ca § + concentration was measured over time 
(Fig.  1). A Ca +§  response was observed with the BV6S7"1 
transfectant  (YP55.49),  but  not with  the  transfectant ex- 
pressing BV6S7"1  G72E (m72), although both transfectants 
expressed equivalent levels of TCRcI~ (3)  and signaled by 
increasing intracellular Ca ++  in response to  a  CD3  mAb. 
This result suggests that HVR-4 is part of the binding site 
for  SEE  presented by  class  II-positive APCs.  Consistent 
with previous results which showed undetectable binding 
of the mAb OT145 to m72 cells (3), there was no Ca §  re- 
sponse to the OT145 mAb, even in the presence of cross- 
linking rabbit anti-mouse (RAM) antibodies (Fig. 1). 
MTV-9  Activates  T  Cells  Expressing  both  BV6S7  Alleles. 
The viral SAG of Mtv-9 was tested as a stable transfectant 
in conjunction with  human HLA  DR1  in mouse  fibro- 
blasts (2).  Co-culture of this transfectant with normal hu- 
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Figure 1.  Intracellular  calcium signaling in response 
to TCP, ligands. YP55.49 and M72 are stable transfec- 
tants of JRT3  (Jurkat subline) expressing wild-type 
BV6S7*I and mutated BV6S7*I G72E (3). The TCR 
(x and [3 chains are otherwise identical. The indicated 
stimuli were added at 60 s. The APC were 8866P B 
lymphoblastoid cells added at a cell ratio of 3:1 (APC: 
Jurkat T cells). 
man T  cells results in expansion of the BV6S7 subset which 
can  easily be  monitored  by staining  the  T  cells  with  the 
monoclonal antibody OT145.  This is a highly specific BV 
response,  as a survey with  a panel of workshop antibodies 
covering over 60% of the TCII. BV repertoire  revealed no 
other  expanded  BV  subsets  in  response  to  Mtv-9  SAG 
stimulation (28). 
Previous studies had shown that individuals homozygous 
for BV6S7"2  had very low levels of OT145  positive  cells 
(4,  21). Together with the poor binding of OT145 to m72 
cells  (3),  this  suggested  that  OT145  preferentially  reacts 
with T  cells  expressing BV6S7"1. 
To determine  whether Mtv-9 prefers to react with one 
or the  other allele  of BV6S7,  cells  from two homozygous 
BV6S7"2 donors and one homozygous BV6S7"1 donor were 
stimulated with the Mtv-9 transfectant.  IL-2 was added on 
day 3 of culture.  On day 10 the T  cells were stained by in- 
direct  immunofluorescence.  As  shown  in  Fig.  2,  T  cells 
from all 3 individuals responded with expansions of OT145 + 
cells.  This  demonstrates  that the Mtv-9 SAG is capable of 
stimulating  T  cells  expressing  either  allele  of BV6S7.  The 
fluorescence intensity of the OT145 staining was 5-10-fold 
greater in the cells derived from donor DNP  (homozygous 
for BV6S7"1) as compared to the two donors homozygous 
for BV6S7"2.  This  was  reproducible  in  five  experiments 
and  demonstrates  the  lesser reactivity of OT145  with  the 
product  of allele  BV6S7"2  (see  above).  In  addition,  the 
magnitude  of the  response  (%  OT145  positive  T  cells)  is 
approximately twofold larger with the BV6S7"1  homozy- 
gous cells. 
To identify the TCR. BV genes used among the OT145+ 
T  cells  responding  to  Mtv-9  SAG,  the  activated  T  cells 
from the experiment shown in Fig. 2 were separated in to 
OT145+  and OT145-  cells  using magnetic beads coated 
with goat anti-mouse  Ig antibody. BV gene usage was as- 
sessed  by RT-PCR  (Fig.  3).  A  striking  predominance  of 
BV6  message  was  found  in  the  Mtv-9  SAG  activated  T 
cells without other BV genes detectable.  The findings were 
identical for both OT145+  and OT145-  cells.  However, 
a  semi-quantitative  RT-PCR.  indicated  that  there  was  at 
1473  Liao et al. Figure 2.  Indirect immunofluorescence staining ofT cells cultured for 10 d with Mtv-9 SAG expressing transfectant cells. The T cell donor genotypes 
were as follows: DNP homozygous for BV6S7*1/1, DP and AA homozygous for BV6S7"2/2. Percentages of positive cells are indicated in each panel. 
The two different levels of staining intensity with OT145 are indicated by arrows. 
least 50-fold more BV6 RNA  in OT145+  cells compared 
with OT145-  cells (data not shown). 
BV6  is the largest human BV family and contains seven 
functional genes (22, 27). It was therefore necessary to ana- 
lyze the  PCP, product by sequencing to  determine which 
BV6  genes were  utilized.  PCP,  products  amplified with  a 
pan-BV6 and BC  (constant region) primer were subcloned 
and sequenced.  We  found that  11/17  sequences from  the 
BV6S7"1  homozygous donor (OT145+  ceils) were BV6S7"1 
with unrelated V-D-J junctions and BJ usage (Fig. 4  A). In 
contrast, sequences from the homozygous BV6S7"2 donors 
yielded BV6S7"2  in  13/17  (Fig. 4  C)  and 9/9  cases  (Fig. 
4  B).  BV6S7  was less frequently represented in the ampli- 
fied BV6 sequences derived from OT145-  cells. It is pos- 
sible  that  T  cells  using BV6  genes  other  than  BV6S7  can 
also  respond to  Mtv-9.  These  other BV6  genes might in- 
clude  BV6S3,  BV6S4,  and  BV6S5  seen  primarily  in  the 
OT145-  subset (Fig. 4, A-C). As the total amount of BV6 
mlq.NA  was  about  50>(  greater  in  the  OT145+  subset, 
transcripts with these alternative BV6 genes must represent 
a  minority of the  T  cells  responding to  the  Mtv-9  SAG. 
The BV sequence data are summarized in Fig. 5.  There are 
some  BV6  genes  that  are  conspicuously  absent  from  the 
Mtv-9-stimulated cells: BV6S1, BV6S11, BV6S14.  As a  con- 
Figure  3.  PCR.  for  indicated 
TCR BV families in cells stimu- 
lated  with  Mtv-9  SAG. The 
source of the cells and the  cul- 
ture  conditions are indicated  on 
the  right  and  lambda  Pstl  size 
markers  (bp) on  the  left. PCR 
product was run on a 1% agarose 
gel  and  stained  with  ethidium 
bromide. The cells analyzed here 
were  OT145-  cells sorted after 
the  10-d culture  (see Fig. 2 and 
methods);  identical  results were 
obtained  with  OT145+  cells 
from the same cell sort. 
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CLONE  BV  gone  CDRIZI  region  BJ 
DNP+6/o  BV6ST*I  CAS  GGSW  NTEAFFC-QGT  BJISI 
DNP+I4/o  BV687"I  CASE GG  YGYTFGSGT  BJIS2 
DNP+27/O  BV6BT*I  CASS PQEL  SGNT~YFGEGS  BJIS3 
DNP+I7/o  BV6S?*I  CASSLC-QGKG  EKLFFGSGT  BJIS4 
DNP+29/O  EV6ST*  1  CASSL GRG  SNQPQHFGDGT  BJIS5 
DNP+7/O  EV6S7  *i  CASSL GGTGIP  QPQHFGDGT  BJIS5 
DNP+25/o  BV687"I  CASE PRTGR  NTGELFFGEGS  BJ2S2 
DNP+I3/o  BV6S7*I  CASS RSTRVSG  DTQYFG~GT  BJ2S3 
DNP+I5/o  BV6ST~I  CASS PTAAITS  IQYFGAGT  BJ2S4 
DNP+II/o  BV6S7  Q  1  CASS QWKS  QETQYFGPGT  BJ2S5 
DNP+30/O  BV6STtl  CASSL GQ  SYEQYFGPGT  BJ2S7 
DNP+34/o  BV6S3  CASE QAGPR  QPQHFGDGT  BJIS5 
DNP+4/o  BV6S3  CAS  IRGGA  ETQYFGPGT  BJ2S5 
DNP+28/O  BV6S4  CASSL AGTE  QETQYFGPGT  BJ2S5 
DNP+36/o  BV6S5  CASE PDS  YGYTFGSGT  BJIS2 
DNP+I2/o  BV6S5  CASS LQNDQ  GYTFGSGT  BJIS2 
DNP+32/o  BV6S5  CASE IASGG  SYEQYFGPGT  BJ2S7 
drip-2 
drip-9 
drip-18  BV6S3 
dnp-ll  BV6S3 
d~p-12  BV6S4 
drip-5  BV6S4 
drip-17  BV6S4 
drip-19  BV6S4 
drip-10  BV6S4 
dnp-4  BV6S4 
dnp-7  BV6S4 
drip-6  BV6S5 
dnp-3  BV6S5 
BV6S7  *i  CASS LKREGT  YEQYFGPGT  BJ2S7 
BV6S7*  1  CASE pTGTGY  YEQYFGPGT  BJ2S7 
CASSL ARGATS NEKLFFGSGT  BJIS4 
CASSL ALGS  DTQYFGPGT  BJ2S3 
CASE QAGGRA  EAFFGQGT  BJISI 
CASE FAGTTS  YTFGSGT  BJIS2 
CASE LTC43S  SYNSPLHFGNGT  BJIS6 
CASE AHRVEAF  NEQFFGPGT  BJ2SI 
CASE DGRW  QYFGPGT  BJ2S7 
CASE LSNQ  YEQYFGPGT  BJ2S7 
CASE PAYGGSG  EQYFGPGT  BJ2S7 
CASE LQNDQ  GYTFGSGT  BJIS2 
CASE FIGSSA  YEQYFGPGT  BJ2S7 
frame  n 
IF  1 
IF  1 
IF  1 
IF  1 
IF  1 
IF  1 
IF  1 
IF  1 
IF  I 
IF  1 
IF  1 
IF  i 
OF  1 
IF  1 
IF  1 
IF  1 
IF  1 
IF  1 
IF  1 
IF  1 
IF  1 
IF  i 
IF  1 
IF  1 
IF  1 
IF  1 
IF  1 
IF  1 
IF  2 
IF  1 
C 
CLONE  BV  gone  CDRITI  region  BJ  gone  fr~  n 
AA+21o  BV687"2  CASSL PR  GANVLTFGAGS  BJ2S6  IF  2 
AA+240  BV6S7"2  CASE STPSGF  LFFGSGT  BJIS4  IF  1 
AA+90  BV6ST*2  CASS LPKAVANK  QYFGPGT  BJ2S3  IF  1 
AA+8o  BV6ST*2  CASS PAGGVRA  KNIQYFGPGT  BJ2S4  IF  1 
AA+4o  BV687"2  CASSL EGTSGRY YNEQFFGPGT  BJ2SI  IF  1 
AA+I20  BV6ST*2  CASSL APTSGRAVA  QYFGPGT  BJ2S5  IF  1 
AA+26O  BV6S7"2  CASS LRGGSY  TEAFFGQGT  BJISI  IF  1 
AA+36o  BV687"2  CAS  RPPG  LNPGELFFGEGS  BJ2S2  IF  2 
AA+34O  BV6BT*2  CASS QGGRGL  YGYTFGSGT  BJIS2  IF  1 
AA+I6  BV6ST*2  CASS YVR  NTEAFFGQGT  BJISI  IF  1 
AA+26  BV6S7"2  CASSL MGPF  YEQYFGPGT  BJ2S7  IF  1 
AA+27  BV6E7*2  CASS PNRAGS  QPQHFGDGT  BJIS5  IF  1 
AA+I9  BV6S7"2  CASSL GLLAGGVCA  QYFGPGT  BJ2S7  IF  1 
AA+31  BV6S4  CASS PQSGLT  SYEQYFGPGT  BJ2S7  IF  1 
AA+33o  BV6S4  CASS RDRA  DTQYFGPGT  BJ2S3  IF  1 
AA+14  BV6S3  CASSL TGT  NEKLFFGSGT  BJIS4  IF  1 
AA+5  BV6S3  CA$S DRLT  YEQYFGPGT  BJ2S7  IF  1 
aa-i  BV687"2  CAgE PRWREQ  QYFGPGT  BJ2S7  IF  1 
aa-17  BV6S7"2  CASSL ESSG  DTQYFGPGT  BJ2S3  IF  1 
aa-15  BV6S7"2  CASS FSGAVRG  EQYFGPGT  BJ2S7  IF  1 
aa-33  BV6S7"2  CASSL AGYP  NTEAFFGQGT  BJISI  IF  1 
aa-20  BV6ST*2  CA3 LAW  DTQYFGP~T  BJ2S3  IF  1 
aa-38  BV6S4  CASE ARVL  NSPLHFGNGT  BJIS6  IF  1 
aa-34  BV6S4  CASSL RQA  SPLHFGNGT  BJIS6  IF  1 
aa-2  BV6S3  CASSL OR  DTQYFGPGT  BJ2S3  IF  1 
aa-16  BV6S3  CASE LAA  SPLHFGNGT  BJIS6  IF  1 
B 
CLONE  BV  gone  CDRIZT  region  BJ  gone  frame  n 
DP§  BV6S7"2  CASE YVR  NTEAFFC-QGT  BJISI  IF  1 
DP+26  BV6S7*2  CASSL VRAF  NTEAF  FGQG  S  BJISI  IF  1 
DP+19  BV687"2  CASE PGGy  GYTFGSGT  BJIS2  IF  1 
DP+22  BV6ST* 2  CASSL RQGT  EQFFG  PGT  BJ2SI  IF  1 
DP+I8  BV6S7"2  CASSL RAGAL  NEQFFGPGT  BJ2SI  IF  1 
DP+6/o  BV6  $7  *  2  CASE RSSS  YNEQFFGPGT  BJ2SI  IF  1 
DP+i/O  BV6ST*2  CAS  RGSA  GANVLTFGAG  S  BJ2S6  IF  1 
DP+2/O  BV6ST*2  CASE LGL  YEQYFGPGT  BJ2S7  IF  1 
DP+I9/o  BV6S7*2  CASE LMGPF  YEQYFGPGT  BJ2S7  IF  1 
dp-3  BV6S7*2  CASE WEGERG  TFGSGT  BJIS2  OF  1 
dp-7  BV6S7*2  CAS TFLGAH  NEQFFGPGT  BJ2SI  OF  1 
dp-24  BV6S7"2  CAS  NLVA  DTQyFGPGT  BJ2S3  IF  1 
dp-26  BV6S?*2  CAS  RGSA  GANVLTFGAG  S  BJ2S6  IF  1 
dp-28  BV6S7*2  CASE FRWD  ETQYFGPGT  BJ2S5  IF  1 
dp-32  BV6S7"2  CAS TRTSGGG  GELFFGEGS  BJ2S2  IF  1 
dp-30  BV6S4  CASS SIQT  NSPLHFGNGT  BJIS6  IF  1 
dp-31  BV6S4  CASS FRY  TGELFFGEGS  BJ2S2  IF  1 
dp-4  BV6S4  CA  RYLALG YNQPQHFGDGT  BJIS5  IF  1 
dp-6  BV6S4  CASS PLDV  ETQYFGPGT  BJ2S5  IF  1 
dp-i  BV6S3  CASE TGQGG  TGELFFGEGS  BJ2S2  IF  1 
dp-23  BV6S3  CASSL TG  TNEKLFFGSGT  BJIS4  IF  2 
dp-27  BV6S3  _ASS TSQVT  NYGYTFGSGT  BJIS2  OF  1 
dp-22  BV6SI  CASE SIH~D  TEAFFGQGT  BJISI  IF  1 
Figure  4.  (A-C)  Sequences of TCB. [3 chains obtained from the PCR_ 
reactions  with  the  pan  BV6  primer  (Fig.  3).  Sequences  were  obtained 
from  the  cultured  cells  of  DNP  (A),  DP  (B),  and  AA  (C),  for  both 
OT145 +  cells  (clones  indicated  as DNP +,  DP +,  or AA +)  and  OT145- 
cells (clones named dnp-,  dp-, aa-) sorted after  the  t0-d culture,  n indi- 
cates the number of times a given sequence was found.  IF/OF indicates 
whether the sequence is in frame or not.  If not, the underlined area indi- 
cates the site at which the sequence comes out of frame. 
Table  1.  BJ Use in BV6S7 Versus Other BV6 TCR 
BJ segments:  1.1  1.2  1.3  1.4  1.5  1.6  2.1  2.2  2.3  2.4  2.5  2.6  2.7  n 
DNP  BV6S7  1  1  t  1  2  1  1  1  1  3  13 
other BV6  1  3  1  1  1  1  1  1  5  15 
DP  BV6S7  2  1  3  1  1  1  2  2  13 
other BV6  1  1  1  1  2  1  7 
AA  BV6S7  3  1  1  1  1  1  1  3  1  1  1  4  18 
other BV6  1  3  2  2  8 
all  BV6S7  6  3  1  2  3  4  3  5  2  3  3  9  44 
other BV6  2  3  3  2  5  1  2  3  2  7  30 
as percent: 
BV6S7  14  7  2  5  7  0  9  7  12  5  7  7  21  100 
other BV6  7  10  0  10  7  17  3  7  10  0  7  0  23  100 
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Figure 5.  Summary  of the fre- 
quency of TCR sequences of the 
indicated BV families.  The seven 
functional BV6  genes contained 
in  the  BV  locus  (Genbank 
L36092) and one  of three  BV6 
pseudogenes (VB6S10) are listed. 
The left hand panels summarize 
data from  Fig. 4  indicating the 
frequency of BV6 genes used by 
OT145+  T  cells (solid bars) or 
OT145-  T  cells (open bars) re- 
sponding to  Mtv-9  SAG in the 
three  donors. The  right  hand 
panels are controls in which the 
same PCR  was performed with 
genomic DNA from two donors 
showing a random pattern of BV 
gene frequency. 
trol  for  variations  in  PCR  efficiency,  some  of these  se- 
quences  could  readily be  amplified from  genomic  DNA. 
Moreover,  an  additional antibody specific for BV6S1  (22) 
failed to stain Mtv-9-activated T  cells (28). 
In unrelated studies effects of BJ encoded (14)  or V-D-J 
junctional  encoded  (13)  amino  acids  on  SAG  reactivity 
have been uncovered.  However, BJ usage was equally dis- 
tributed among BV6S7  and  other BV6  TCRs  in  all three 
donors  tested with  only a  few possible exceptions: BJ1S6 
was  used by 0/44  BV6S7  sequences,  but  5/30  other BV6 
sequences,  and BJ2S6 was used by 3/44 BV6S7  sequences, 
but  0/30  other  BV6  sequences  (Table  1).  There  is  no 
amino  acid motif from  the  V-D-J  or  the J  region  that  is 
shared exclusively by BV6S7 sequences and not other BV6 
sequences (Fig. 4) and it seems unlikely that the minor dif- 
ference in BJ usage reflects preferences of the SAG. 
SEE  and  0TI45  mAb  Each  Preferentially  Activate  the 
B V6S7* 1 Allele.  To  distinguish  between  reactivity pref- 
erences  of the  SAGs and  of the  mAb  OT145,  an  experi- 
mental  system  was  needed  that  did  not  rely  on  OT145 
staining  or  sorting  and  in  which  cells  expressing  both 
BV6S7 alleles were present. Therefore, T  cells from BV6S7 
heterozygous  donors  were  stimulated  with  either  SEE, 
Mtv-9  SAG  or  OT145  and  cultured  with  IL-2  for  10  d. 
Expansion  of T  cells using BV6S7"1  versus BV6S7"2  was 
then  measured  by  RT-PCR  with  two  BV6S7-specific 
primers,  of which  the  upstream  primer  was  end-labeled 
with  32p  (the  amplified  fragment  is  237  bp).  The  PCR 
product of the BV6S7"1  allele contains a BamHI site. After 
BamHI  digestion the  labeled upstream  fragment  (189  bp) 
migrates faster (Fig. 6). To control for partial BamHI diges- 
tion,  PCR  amplified DNA  from  a  BV6S7"1  homozygous 
donor was used (DNP,  Fig. 6 A). Mtv-9 and PHA stimula- 
tion of T  cells from a  heterozygous donor (SF) resulted in 
expression  of both  BV6S7  alleles (Fig.  6  A).  By  contrast, 
OT145  stimulation led to  a  marked  shift to  BV6S7"1  ex- 
pression. 
To assess the effect of SEE in this system, BV8 positive T 
cells need  first he  removed,  as  this  BV  subset  is  the  pre- 
ferred target of SEE  (29).  Effects of SEE on BV6S7  T  cells 
1476  TCR Binding Differs for SEE and Mtv-9 SAG Figure 6.  BV6S7*I and BV6S7"2 usage among polyclonal T  cells stimulated with Mtv-9 SAG, SEE, SEA, PHA and OT145. Labeled PCR products 
digested with BamHI are shown on the right and the quantitative scanning image on the left with the percentage of  signal corresponding to BV6S7"1. A, 
B, and C represent different experiments with T  cells from two different heterozygous donors. In A  cells were stimulated for 10 d with the indicated con- 
ditions and then harvested for RT-PCR.. In B and C the cells were first stimulated with Mtv-9 SAG and cultured for 10 d and then restimulated with the 
indicated ligands and cultured for 7 d. B shows staining with OT145 and (C) RT-PCP, for the two BV6S7 alleles. The 5% signal for BV6S7"2 in the "1/'1 
homozygous donor represents background due to incomplete BamHI digestion. "AM ex vivo" represents RNA isolated from fresh PBL and indicates the 
baseline distribution of the two alleles in this heterozygous donor. In D  the experiment was repeated with the SEE D19 and SEA C19 mutants. Dtkl  de- 
notes stimulation with a DAP-DRBI"OIO1/DRA transfectant as a control for the Mtv-9 SAG transfectant which also expresses with DRBI*0101. AM 
has a DRBI*0102, DR.Bl*1301 genotype by PC1Z (courtesy of Dr. D. Kostyu, Duke University). The numbers indicate reladve percentages for expres- 
sion of the two BV6S7 alleles. Figure  7.  Sequence of SEA, 
SEE and SEB in the region be- 
tween the [310 strand and the e~5 
helix. The numbering is that of 
each  superantigen.  The  circled 
SEE residues are thought to play 
a  role  in  determining  the  BV 
specificity of SEE. 
can otherwise  not be discerned,  presumably because inter- 
action  with  BV6S7  T  cells  is  of lower  affinity.  Therefore 
BV6S7-expressing T  cells from a heterozygous donor were 
first  expanded  by stimulation  with  Mtv-9  and  cultured  in 
IL-2 containing medium for 10 d:  on day 7  OT145+  cells 
represented  27%  of  all  CD3+  cells.  On  day  8  BV8- 
expressing cells (~3%) were removed with magnetic beads. 
On day 10 the cells were washed and a second culture was 
initiated with the additives listed.  On day 17  the cells were 
stained  (Fig.  6  B)  and  RNA  was  harvested  for  RT-PCR 
(Fig. 6  C). At this time each culture contained an expanded 
subset of OT145+  cells (Fig. 6/3) but BV8 expressing cells 
were undetectable  (not shown). BV6S7  allele usage was not 
skewed in cells stimulated with Mtv-9  or with  the  control 
SAG SEA  (Fig.  6  C).  SEE used at two different concentra- 
tions  favored  expression  of BV6S7"1.  OT145  stimulation 
resulted  in  nearly  exclusive  expression  of BV6S7"1.  To 
control  for  the  possible  effects  of DR1  expressed  on  the 
Mtv-9 transfectant,  we used cocultures with DAP-DR1  fi- 
broblasts  (with  no  SAG)  and  cocultures  of SEE  presented 
by DAP-DR1  fibroblasts. Similar results to those in Fig. 6  C 
were  obtained.  Together  with  the  results  of  the  Jurkat 
transfectants  in  Fig.  1,  we  conclude  from  these  data  that 
both SEE and OT145  react preferentially with allele "1. 
Position 72 of TCR BV6S7 Lies in Close Proximity to Resi- 
dues 203-204 of SEE.  Previous  work  has  identified  two 
adjacent  positions  in  SEE  and  SEA  that  impart  specificity 
for BV  encoded  regions  (17-19).  Thus,  BV specificity was 
exchanged  between  SEE  and  SEA  by  replacing  only  2-3 
residues in an exposed loop between  13 strand 10 and oL he- 
lix  5  (18).  Therefore we used  SEE D197G  P203S  D204N 
(D19), which has acquired the specificity or SEA, and SEA 
$206P  N207D  (C19)  with  the  acquired specificity of SEE, 
to  see  whether  BV6S7  cells were  stimulated  and  whether 
there was a preference for either allele of BV6S7.  Fig.  6  D 
demonstrates  that  SEA  and  D19  gave  less  stimulation  of 
BV6S7  cells  as indicated  by low  intensity  PCR  bands  and 
lower  percentage  of OT145+  cells  by  FACS  |  (data  not 
shown).  Both  alleles  of BV6S7  were  equally  represented. 
By contrast SEE and C19 were more stimulatory and levels 
ofBV6S7*I  RNA were predominant over BV6S7"2 in 3/3 
experiments.  C19  usually  showed  even  greater  preference 
for allele "1 than SEE itself. 
These results indicate  that the ability to discriminate be- 
tween  G72  and  E72  of the  TCR  [3  chain  HVR-4  lies  in 
residues  P203  and  D204  of SEE  (Fig.  7).  Therefore,  this 
region of SEE  is likely in close proximity of HVR-4  posi- 
tion 72.  This constrains the possible conformations ofa tri- 
molecular  complex  (MHC-TCR-SEE)  and  is  most  com- 
patible  with  a  position  of SEE  similar  to  that  of SEB  and 
TSST1  relative to MHC  class II, e.g., adjacent to the c~ he- 
lix of the o~1 domain of MHC  class II (30,  31). 
Discussion 
This  paper addresses  three  unresolved  questions.  (a)  Do 
all SAGs, including  bacterial  (bSAG)  and viral  (vSAG), in- 
teract in the same way with TCR  residues or not? (b) What 
is the relative position of the TCR  within the tri-molecular 
complex and is it variable from one complex to another?  (c) 
Do  naturally  occurring  allelic  variants  of TCR  BV  genes 
differ functionally? 
Variable SAG-interactive Sites on TCR ~  Chain.  Generally, 
SAGs are thought  to bind to the lateral surface of the TCR 
13 chain  and in particular  to residues  of the  HVR4  region. 
Positions 73/74  (adjacent to position 72 investigated in this 
study)  were  implicated  by  mutagenesis  in  binding  of 
mBV8S2 to Mtv-7 vSAG  (7)  and in binding of mBV17  to 
Mtv-9  vSAG  (9).  HVR4  was  shown  to  impart  specificity 
for the bSAGs SEC2  and  SEC3  by molecularly transplant- 
ing 11  HVP-,4 residues of the reactive BV13S2  to the non- 
reactive BV13S1  which  then acquired SEC2 and SEC3  re- 
activity (8).  Thus,  both vSAG and bSAG seem to focus on 
the TCR  HVR4 region. 
Early studies  with  the vSAG of Mtv-7  showed that gly- 
cosylation of N  residues  18, 20, and 74 ofmBV8S2  (16,  18, 
and 71  in original reference)  inhibited  reactivity with Mtv-7 
(7).  However,  several bSAGs  showed  equivalent  dissocia- 
tion constants for binding of glycosylated versus unglycosy- 
lated mBV8S2 in a recent BIAcore binding study  (32).  Al- 
though  Mtv  vSAG  were  not  examined  in  this  study,  the 
implication  is  that  the  vSAG  of Mtv-7  may  differ  from 
bSAGs in  terms  of the  TCR  contact  residues  of mBV8S2 
used. 
Herein we show that a bSAG (SEE)  and a vSAG (Mtv-9) 
differ in fine specificity for human TCRBV6S7.  This TCR 
gene  is  naturally  allelic.  The  vSAG  of Mtv-9  stimulated 
both alleles equally well, but the bSAG, SEE, preferentially 
reacts  with  the  BV6S7"1  allele.  A  monoclonal  antibody, 
OT145,  also has preferential  reactivity with  this  allele.  Al- 
though  there  are  two  amino  acid  differences between  the 
two  alleles, the single residue  important for preferential re- 
activity of both ligands is position 72 (Fig.  1), at the apex of 
HVR-4,  right between  13 strands D  and E  at a sharp turn in 
the carbon backbone of the TCR  [3 chain  (3,  33). BV6S7"1 
encodes G72 and BV6S7"2 encodes a negatively charged E72. 
1478  TCR Binding Differs for SEE and Mtv-9 SAG Figure 8.  Model of  BV6S7*I and BV6S7"2 based on coordinates ofmBV8S2 beta chain (38). 26 residues of the mouse beta chain variable region were 
substituted with the human sequence excluding the CDRIII region which was not altered. The coordinates were recalculated with the program Modeler 
(48). For both human BV6S7 proteins the carbon backbone closely overlaps that of the original mouse beta chain with the exception of $62 which rep- 
resents a supplementary amino acid as the human BV6S7 sequences are one residue longer than the mBV8S2. The image was created with InsightlI and 
shows BV6S7"1 on the left and BV6S7"2 on the right; CDRI =  green, CDRII = magenta, CDRIII = yellow, HVR4 =  orange, E/G72 = white (with 
side chain). The side chain of N52 in CDRII and the exposed surface for CDR1, CDR2, and HVR4 are shown. 
The  difference in  fine specificity between  SEE  and  the 
vSAG of Mtv-9 means that each SAG interacts differently 
with  the  same  TCR.  In fact,  others have  described TCR 
BV mutations that affect different SAGs in opposite ways. 
For instance m_BV10  T26A resulted in diminished reactiv- 
ity with SEC2 but not with ExT and L27A decreased reac- 
tivity  with  ExT  but  not  SEC2  (34).  In  the  D10  TCR 
mBV8.2  N24H  allows  recognition  of Mtv-7  SAG  and 
SEB,  but wild-type N24  allows recognition of only SEB. 
In the same TCR  G51V G53D allows recognition of SEB, 
but not SECI_3, which are all recognized by the wild-type 
TCR  (35).  Finally, TCR  ~3  chains  expressing various BV 
genes, each known to provide for reactivity with the same 
SAG,  do  not  share  common  residues  when  comparing 
modeled  structures  based  on  the  crystal  structure  of the 
TCR  (3  chain  (32).  One  explanation for these data is that 
there are several distinct binding sites for the same SAG de- 
pending on the TCR  involved. 
It is possible that there are subgroups of SAGs that inter- 
act  with  TCR  13  chain  in  a  similar  way.  Such  distinct 
groups might include the group ofMtv vSAGs, the bSAGs 
with two MHC  class II binding sites of which one is Zn ++ 
dependent  (e.g.,  SEA),  or the  bSAGs with  a  single MHC 
class II binding site (e.g., SEB,  TSST-1).  For instance SEA 
cross-links MHC  class  II  molecules  (36,  37).  With  SAG 
molecules on both sides of an MHC  class II molecule the 
position of the TCR  may be constrained. 
There  are  several possible  explanations  for  the  relative 
lack  of reactivity of BV6S7"2  with  SEE  and  OT145.  A 
simple hypothesis is that the shape of the HVR4  region is 
modified in the absence of a large charged R  group at posi- 
tion  72.  This  was  examined  (Fig.  8)  by  comparing  the 
modeled structure  of the  two  human  TCR  BV6S7  alleles 
using the crystal coordinates of a mouse TCR  ~  chain (38). 
The  model  shows  no  positional differences in  the  carbon 
backbone of HVR4  and the CDR  loops between the two 
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alleles. The large charged side chain of E72 lies in a trough 
bordered by CDRI,  CDRII,  and HVR4  residues (Fig. 8). 
Thus the reactive BV6S7"1  allele, encoding G72  (with just 
a hydrogen as a side chain), is characterized by a surface de- 
pression which could accommodate an SEE residue. BV8, 
the  favored  target  of SEE  encodes  A72,  also  with  a  very 
small side chain  (CH3).  In contrast,  the depression is filled 
in  BV6S7"2  with  the  charged  side  chain  of E72  (CH2- 
CH2-COO- ).  The  oxygen  atoms  of E72  are  potential 
electron  donors,  but  the  closest  individual  atoms,  from 
CDRI  (H24)  or CDRII  (Q51),  are at a distance of 3.36 A 
or greater.  Thus  hydrogen bonds  and salt bridges are  un- 
likely and E72 is probably fially charged at a physiological  pH. 
An  alternative  hypothesis  is  that  the  critically located 
charge  at  E72  might  result  in  electrostatic repulsion  be- 
Table 2.  Alignment of  HVR  4  from the 7 BV6 Genes, BV16 and 
mB V8S2 
68  76 
BV6SI  VRPEGSVST 
BV6S3  ERPEGSVST 
BV6S4  ERPEGS  I  ST 
BV6S14  ERPEGS  I  ST 
BV6SI  I  ERPERSVST 
BV6S5  _ERPKGSLST 
BV6S7"I  ERTGGSVST 
BV6S7"2  E  RTGE_SVST 
BV16SI  ERTGGTYST 
BVSSI  KMPNASF  ST 
mBV8S2  S  RP  S  QENF  S 
Acidic residues are underlined and basic residues are in bold. Figure  9.  Model of SAG/MHC/TCR  complex demonstrating the 
SAG wedge between TCR and MHC II. The CDR loops of the TCR ~x 
chain are not shown. 
tween  TCR  [3  chain  and  the  SAG.  BV8,  like  BV6S7*I, 
does  not  encode  a  charged  residue  at  the  apex  of the 
HVR4 region (Table 2). The negative charge of E72 could 
prevent interaction with  SEE  due  to a negatively charged 
SEE residue.  Two amino acids of SEE that determine BV 
specificity have been mapped (17-19).  The SAGs SEE and 
SEA  are  closely related  (82%  identity)  but  have  different 
BV specificities. Thus,  SEA mutated at two residues  (SEA 
$206P  N207D)  to  emulate the  sequence  of SEE  (Fig.  7), 
resulted in gain of the BV8 and BV5S1 specificities of SEE. 
The reverse result was obtained with SEE mutated to look 
like SEA, SEE D197G P203S,  D204N  (SEE  residue num- 
bering), e.g., gain ofBV5S3, BV7S4, and BV9S1  specifici- 
ties of SEA. Therefore, it is possible that D204 of SEE may 
lie in close proximity of position 72  of the TCR  [3 chain. 
In support of this, Mariuzza and colleagues have found that 
the  equivalent  regions  of SEC3  and  mBV8S2  form close 
contacts in a co-crystal (personal communication). 
Relative  Position of  TCR  within  the  Tri-molecular Com- 
plex.  SEE has not yet been crystallized. However, a crys- 
tal structure of the related SEA (39) and a co-crystal of SEB 
(30) and TSST1  (31) with HLA DR1  have been described. 
The SAG structures are in general quite similar, in particu- 
lar the region corresponding to SEE196_204 which represents 
a solvent exposed loop linking the [310 strand to the c~5 he- 
lix  (39-41),  see Fig.  7.  In the  SEB-DR1  co-crystal struc- 
ture  (30)  this loop protrudes such that it overlies the HLA 
DR1 0t helix of the c~1 domain (DR1 residues cx51-~x57) in 
a position where  it could bind to  TCR  [3  chain residues. 
Using  this  model  and  assuming  close  proximity between 
residue E72 of the TCR [3 chain and residue D204 of SEE, 
the TCR [3 chain CDRI and CDRII would be placed over 
the  MHC  or1  domain and  the  CDRI  and  CDRII of the 
TCR a  chain on the e~ helix of the MHC [31 domain con- 
sistent with some models of TCR/MHC  positioning  (42, 
43).  However, a recent model of TCR  positioning, based 
on  recognition  of variant  conalbumin  peptides  presented 
by IE  k (44),  places the TCR  [3 chain and HVR-4 over the 
COOH-terminal portion of the peptide which is inconsis- 
tent  with  binding  to  known  SAG  TCR  interaction  sites 
and the SAG/DR1  co-crystal data. If these results are gen- 
erally valid for nominal  Ag/MHC  recognition,  it follows 
that the rotational orientation of the TCR differs  between 
Ag/MHC versus SAg/MHC recognition.  In addition,  it is 
likely that the axial orientation of the TCR differs  because 
SAGs, specially TSST1  (31),  occupy space above the  class 
II c~ helix of the al  domain and thus are probably wedged 
in between TCR and MHC on one side. This is consistent 
with our data, as position 72 of HVR4 would lie on top of 
SEE D204 in stead of making contact with MHC  class II 
residues (Fig.  9). 
Other  TCR  Regions  That  Contribute  to  SAG  Recogni- 
tion.  The actual TCR  residues of BV6S7*I  that mediate 
binding to SEE probably include  additional residues  beyond 
residue 72,  because the  HVR4 motif ERTGGxxST68_76 is 
shared with BV16  (Table 2) which is neither SEE,  Mtv-9 
or OT145 reactive (3, and data not shown). Moreover, re- 
activity of OT145 and SEE with BV6S7  is not completely 
inhibited in the presence of E72.  Thus the interaction be- 
tween TCR HVR-4 and these ligands is presumably more 
complex and involves TCR residues other than position 72. 
TCR residues implicated in SAG reactivity by mutagen- 
esis experiments generally do not affect Ag/MHC reactiv- 
ity,  and vice versa  (45).  However,  from studies  of SAG/ 
TCR  combinations  of presumed  "lower  affinity,"  where 
an effect of the presenting MHC class II is readily seen, it 
has become clear that residues beyond HVR4 and the lat- 
eral surface of the TCR [3 chain are involved in determin- 
ing SAG reactivity, such as residues in TCR  [3  CDRI-III 
(10, 11, 13, 14, 34) and residues of the TCR oL chain (46, 47). 
It  is  therefore  important  to  avoid drawing  conclusions 
based solely on experiments with transfected T  cell clones 
in which a single TCR is expressed. SEE has low reactivity 
with BV6S7 TCRs (compared with BV8) and it was there- 
fore useful to confirm the transfectant data (Fig.  1) with an 
assay  using polyclonal  T  cells  from heterozygous  donors. 
The RT-PCR  assay described for detection  of BV6S7  al- 
leles (Fig.  6) has not been previously used to monitor SAG 
responses. Results are independent  of all other TCR vari- 
able gene segments  (BD,  BJ, AV, AJ)  used by T  cells  re- 
sponding to the  SAG, because polyclonal T  cells are used. 
Any possible effect of MHC alleles (25) can be ruled out by 
using T  cells from HLA disparate donors. Thus this system 
1480  TCR Binding Differs for SEE and Mw-9 SAG allows  one  to  detect  discrete  differences  in  TCR  usage 
(BV6S7 alleles) in a SAG response ofpolyclonal T  cells. 
Evolutionary Significance of TCR BV AUeles.  The data dem- 
onstrate that two  naturally occurring alleles of a  TCR  BV 
gene differ in their functional reactivity with natural ligands 
such as the bacterial superantigen SEE derived from Staphy- 
loccocal aureus,  a  common  human  pathogen.  Most  normal 
adults  have  antibodies  to  staphylococcal SAGs  indicating 
prior exposure. Therefore it is likely that the TCR  BV6S7 
alleles evolved due  to ligand interactions leading to selec- 
tive advantages of one allele versus the other, as opposed to 
neutral mutations and genetic drift. 
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